Clinical Trial Update: Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer [Phase 3]

View source ↗

Summary

Agenus Inc. reports that its Phase 3 trial of a personalized cancer vaccine for non-metastatic kidney cancer (NCT00126178) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Personalized cancer vaccine

Snippet

Sponsor: Agenus Inc. | Conditions: Kidney Cancer, Renal Cell Carcinoma | Phase 3 | Status: TERMINATED